Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Collegium Pharmaceutical Stock Up 0.7 %
Shares of NASDAQ:COLL opened at $37.38 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The company has a market capitalization of $1.20 billion, a P/E ratio of 15.58 and a beta of 0.94. Collegium Pharmaceutical, Inc. has a 52-week low of $20.95 and a 52-week high of $40.95. The stock’s fifty day simple moving average is $35.65 and its 200-day simple moving average is $35.41.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The company had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. During the same period in the prior year, the firm earned $1.13 EPS. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Collegium Pharmaceutical
Wall Street Analysts Forecast Growth
COLL has been the subject of several research reports. HC Wainwright lifted their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Truist Financial lifted their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Piper Sandler restated a “neutral” rating and set a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.60.
Read Our Latest Report on COLL
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Further Reading
- Five stocks we like better than Collegium Pharmaceutical
- The 3 Best Blue-Chip Stocks to Buy Now
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Investing in Travel Stocks Benefits
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Insider Buying Explained: What Investors Need to Know
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.